Agilisium Joins Anthropic's Claude Partner Network as Select Services Partner

Agilisium Named Select Services Partner in the Claude Partner Network

On July 22, 2026, Agilisium, a renowned Context-Centric AI company known for its innovative approach in the Life Sciences sector, made waves with the announcement that it has achieved Select Services Partner status in Anthropic's Claude Partner Network. This recognition underscores Agilisium's robust track record in deploying Claude-powered AI solutions specifically tailored for Life Sciences clients.

The partnership signifies a transformative step for Agilisium, which effectively combines its FDX (Forward Deployment Expert) framework with Claude’s advanced reasoning capabilities. This collaboration aims to create significant business impacts for clients in the Life Sciences sector, facilitating effective AI application within production environments, notably through platforms like Amazon Bedrock.

A Strategic Investment in AI Development

As part of its commitment to advancing AI in Life Sciences, Agilisium previously announced a substantial investment of $5.5 million aimed at enhancing its FDX model. This initiative emphasizes embedding AI expertise directly into client organizations while addressing four critical dimensions: Domain, AI and Technology, Consultative Solutioning, and Systems and Process Thinking.

Under this initiative, Agilisium is training its FDX practitioners on Claude's platform, positioning it as the go-to AI solution within the FDX delivery framework for Life Sciences. The company is also in the process of establishing the Agilisium Claude Life Sciences Center of Excellence, which will feature Context-Centric Transformation Labs focusing on vital areas such as Clinical Development, Regulatory Affairs, Medical Affairs, Pharmacovigilance, and more.

The Importance of Contextual Understanding

Agilisium’s approach highlights the importance of providing AI with context. The company believes that successfully telling AI what its industry is, and how an enterprise operates, sets the foundation for real progress. This strategic integration of Claude and FDX is designed to empower pharmaceutical and biotech organizations to transition from high-level AI ambitions to actual, enterprise-grade outcomes.

Raj Babu, CEO and Founder of Agilisium, remarked on the significance of this partnership: “In Life Sciences, the cost of incorrect AI deployment extends beyond commercial metrics and into patients’ well-being. Our FDX framework, when paired with Claude's sophisticated reasoning abilities and contextual depth, establishes a crucial foundation for navigating the complex environments we serve.”

Moreover, Babu highlighted that this partnership recognizes the team’s dedication to fostering a deeper collaborative effort, one that centers on meaningful outcomes for their clients.

A Path to Enterprise-Grade AI Solutions

Arunkumar Arjunan, Chief Operating Officer and Chief AI and Innovation Officer at Agilisium, emphasized the venture’s long-term vision, aiming to cultivate one of the most sophisticated implementations of Claude within Life Sciences. He stated, “This goes beyond merely joining a partner network. We are committed to enabling our clients to harness enterprise-level AI solutions that are validated for regulated environments and drive innovation at scale.”

About Agilisium

Agilisium prides itself on being the first consulting service dedicated exclusively to Life Sciences, offering advanced Context-Centric AI solutions that focus on delivering impactful changes across the value chain. Their service suite enables clients to accelerate drug discovery, optimize patient care, streamline product delivery, and foster cross-organizational collaboration. The company’s commitment to excellence and innovation positions it as a leader in shaping the future of the Life Sciences industry.

For further inquiries and insights into their offerings, interested parties can visit www.agilisium.com.